Send me a link:

*Text messaging rates may apply.

 Dow Up0.13% Nasdaq Down0.10%

Eventide Healthcare & Life Sciences A (ETAHX)

15.62 Down 0.30(1.88%) Jul 28

Profile as of Jun 29, 2014Get Profile for:
Eventide Healthcare & Life Sciences A
630-a Fitzwatertown Road2nd Floor
Map
Phone: 877-771-3836
Fund Overview 
Category:Health
Fund Family:Eventide Funds
Net Assets:118.23M
Year-to-Date Return:7.83%
Yield:0.00%
Morningstar Rating:N/A
Fund Inception Date:Dec 27, 2012
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Finny Kuruvilla
Lead Manager since Dec 27, 2012
Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT. Finny Kuruvilla has been a co-portfolio manager for the Eventide Gilead Fund since inception in July 2008 & manager of the Eventide Healthcare & Life Sciences Fund since inception in December 2012. Dr. Kuruvilla is also currently a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm.
Investment Information 
Min Initial Investment:1,000
Min Initial Investment, IRA:1,000
Min Initial Investment, AIP:100
Min Subsequent Investment:50
Min Subsequent Investment, IRA:50
Min Subsequent Investment, AIP:50
ETAHX can be purchased from 18 brokerages.

Fund Summary 
The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

Fund Operations 
Last Dividend : N/A
Last Cap Gain : N/A
Annual Holdings Turnover : N/A
Average for Category:53.49%
Fees & Expenses 
ExpenseETAHXCategory Avg
Annual Report Expense Ratio (net):1.68%1.38%
Prospectus Net Expense Ratio:1.69%N/A
Prospectus Gross Expense Ratio:9.56%N/A
Max 12b1 Fee:0.25%N/A
Max Front End Sales Load:5.75%5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:2,514655
5 Yr Expense Projection*:4,1331,028
10 Yr Expense Projection*:7,5782,020
* Per $10,000 invested